Imagine a
world without allergies
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead development programs include treatments for birch pollen, grass pollen and peanut allergies.
Desentum’s products are investigational and not approved for marketing in any region.
Technology
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
Desentum
Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
News
Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland
Desentum’s 18 M€ share issue organised by the Finnish growth equity company Springvest marks the largest public share issue ever conducted in Finland by an unlisted growth company. The company is advancing a novel allergen immunotherapy platform that has the potential to make AIT treatments faster, more effective, and safer.
New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
A single Ara h 2 allergen can bind simultaneously three copies of an IgE antibody commonly found in peanut allergic patients. This enables the formation of large allergen-IgE complexes on mast cell or basophil surfaces and contributes to the potency of Ara h 2 in triggering allergic reactions and highlights its role in anaphylaxis.
Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its...